Immunology

Latest News

AChR-Ab titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. | Image credit: luchschenF - stock.adobe.com

AChR-Ab Titers Associated With Myasthenia Gravis Severity

By Rose McNulty

February 21st 2025

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.

Hidradenitis suppurativa. | Image Credit: MdBabul - stock.adobe.com

Bimekizumab for Hidradenitis Suppurativa Offers Durable Disease Control in Long-Term Data

By Cameron Santoro

February 13th 2025

Myasthenia gravis | Image Credit: © Yurii Kibalnik-stock.adobe.com

Phase 3 Data Support Nipocalimab for Myasthenia Gravis

By Maggie L. Shaw

February 7th 2025

Jeff Stark, MD, UCB

Dr Jeff Stark: New Bimzelx Dose Offers Simplicity and Choice

By Maggie L. Shaw
Jeff Stark, MD

February 6th 2025

Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine

How FcRn Blockade Targets Myasthenia Gravis Autoantibodies

By Maggie L. Shaw
Katie Abouzahr, MD

January 29th 2025

More News

Rheumatoid arthritis | Image: LinkedIn

August 5th 2024

Understanding Inflammatory Pathways to Address CV Risk in Patients With Autoimmune Disease

A session on the final day of the 2024 Congress of the American Society of Preventive Cardiology explored the connections between autoimmune disease and cardiac events.

In the pooled analysis, ankylosing spondylitis was associated with a greater risk of cancer occurrence. | Image credit: Lila Patel - stock.adobe.com

July 26th 2024

Meta-Analysis Finds Link Between Ankylosing Spondylitis, Cancer Risk

The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.

myasthenia gravis | Image Credit: Николай Зотов-stock.adobe.com

July 21st 2024

Chinese Patients With gMG Respond Well to Efgartigimod

Jared Kaltwasser

A new report offers safety and efficacy data on a population with generalized myasthenia gravis (gMG) not represented in the drug’s pivotal phase 3 trial.

Arthritis in hands - stockdevil - stock.adobe.com

July 20th 2024

Persistently Active Rheumatoid Arthritis Linked With Socioeconomic Factors

Factors independently associated with persistently active RA included age, gender, previous or current smoking status, and social deprivation.

The review identified several challenges to quality rheumatoid arthritis treatment, along with potential interventions to improve care. | Image Credit: MicroOne - stock.adobe.com

July 18th 2024

Gaps in Rheumatoid Arthritis Care Quality Exist in North America

A literature review plus in-person visits helped identify barriers to quality rheumatoid arthritis care, as well as effective interventions to improve care quality.

Book about myasthenia gravis | Image Credit: mdaros-stock.adobe.com

July 16th 2024

Promising Results for Efgartigimod in Myasthenic Crisis

Kimberly Rath, PharmD

A new case report details the successful use of efgartigimod as a rescue medication in a patient with therapy-refractory myasthenic crisis.

Physical therapy on treadmill | Image credit: Justlight - stock.adobe.com

July 9th 2024

Exercise Therapy Can Reduce Symptoms, Disease Activity in Axial Spondyloarthritis

Patients with axial spondyloarthritis who took part in exercise therapy showed improvements in disease activity and symptoms compared with patients who did not, a meta-analysis found.

Patient rubbing sore hands with rheumatoid arthritis | Image credit: Evrymmnt - stock.adobe.com

July 3rd 2024

Patient-Reported Pain Improvement Linked With Remission in Rheumatoid Arthritis

Pain improvement was associated with remission or low disease activity in patients undergoing treatment for rheumatoid arthritis, a study found.

Obesity was linked with worse patient-reported pain outcomes in rheumatoid arthritis. | Image credit: 9nong - stock.adobe.com

July 1st 2024

Obesity Linked to Worse Patient-Reported Outcomes in Rheumatoid Arthritis

Abigail Brooks, MA

Patients with rheumatoid arthritis and obesity exhibited worse scores for subjective measures like pain and fatigue compared with those without obesity.

Spine MRI - Kondor83 - stock.adobe.com

June 29th 2024

Preexisting Structural Damage, Inflammation Linked With Radiographic Progression in Patients Treated for AxSpA

Preexisting spinal damage and higher levels of inflammatory activity at baseline were linked with radiographic progression in axial spondyloarthritis treated with biologic disease-modifying antirheumatic drugs over 2 years regardless of treatment type.

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nr-axSpA and AS. - natali_mis - stock.adobe.com

June 28th 2024

Bimekizumab Shows Long-Term Efficacy in Nonradiographic AxSpA, Ankylosing Spondylitis

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).

Back pain due to spondyloarthritis- fizkes - stock.adobe.com

June 22nd 2024

AxSpA Treatment Intensification in Practice Linked With Higher ASDAS Cutoff Than Recommended

In the clinical practice setting, intensifying treatment for axial spondyloarthritis (axSpA) is associated with a higher Ankylosing Spondylitis Disease Activity Score (ASDAS) cutoff value than recommended, new research found.

Efgartigimod alfa and hyaluronidase is now FDA approved for the treatment of adults with CIDP. | Image credit: wladimir1804 - stock.adobe.com

June 21st 2024

FDA Approves Efgartigimod Alfa and Hyaluronidase for CIDP

The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Sarilumab FDA Approved for Active Polyarticular Juvenile Idiopathic Arthritis

June 11th 2024

Sarilumab FDA Approved for Active Polyarticular Juvenile Idiopathic Arthritis

The approval brings a new treatment option to pediatric patients with polyarticular juvenile idiopathic arthritis, which is a form of arthritis affecting multiple joints at the same time.

Woman with back pain | Image credit: vectorfusionart - stock.adobe.com

June 7th 2024

Study Suggests TNF Inhibitor Use Is Cardioprotective in Radiographic Axial Spondyloarthritis

Tumor necrosis factor (TNF) inhibitor use was associated with a lower risk of cardiovascular outcomes in patients with radiographic axial spondyloarthritis in a recent study.

Woman sleeping next to alarm clock | Image credit: stokkete - stock.adobe.com

May 31st 2024

Pain Linked With Poor Sleep Quality, Comorbidities in RA, PsA

Among patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), intense pain symptoms were associated with poor sleep, fibromyalgia, depression, and sleep apnea.

Blood analysis | Image credit: Parilov-stock.adobe.com

May 31st 2024

Novel Serum Biomarkers Show Potential for Diagnosing, Monitoring Axial Spondyloarthritis

A recent review highlighted several candidate biomarkers for diagnosing axial spondyloarthritis associated with inflammatory bowel disease in early phases.

Concept of hidradenitis suppurativa | Image credit: syahrir - stock.adobe.com

May 24th 2024

Bimekizumab Elicits Clinically Meaningful Responses in Moderate to Severe Hidradenitis Suppurativa

Newly published findings from the pivotal phase 3 BE HEARD I and BE HEARD II trials demonstrated that bimekizumab was well tolerated and produced clinically meaningful responses in patients with moderate to severe hidradenitis suppurativa.

Drug costs | Image credit: nikitos - stock.adobe.com

May 20th 2024

IQVIA Report Highlights Shifts in Medicine Use, Spending Across Therapy Areas

Areas of focus in the annual report included health system utilization and recovery from the pandemic, patterns of medicine use, drug pricing, and patient out-of-pocket costs.

Document with denied - G_stockerthailand - stock.adobe.com

May 10th 2024

Research Shows Prior Authorization Denials Delay Critical Immunology Care

Giuliana Grossi

Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.

Young Woman Sitting | Image Credit: Bungon - stock.adobe.com

May 3rd 2024

Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis

Giuliana Grossi

Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.

Man Feeling Back Pain | Image Credit: Mantinov - stock.adobe.com

April 30th 2024

Bimekizumab Shows Sustained Efficacy in Treating Axial Spondyloarthritis for 52 Weeks

Giuliana Grossi

Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.

Brain illustration in blue and pink | Image credit: jolygon - stock.adobe.com.jpg

April 17th 2024

Cognitive Impairment Screening in the Clinic for Patients With SLE

Laura Joszt, MA

Screening for cognitive impairment among patients with systemic lupus erythematosus (SLE) can be challenging; however, some shorter assessments have shown promise for use in the clinical setting.

White plastic bottle with medical pills | Image Credit: encierro - stock.adobe.com

April 12th 2024

NSAIDs vs bDMARDs: Sex Disparities in Treatment Initiation for Axial Spondyloarthritis

Giuliana Grossi

New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.

Woman sitting on bed with back pain illustrated by a highlighted spine | Image credit: WavebreakMediaMicro - stock.adobe.com

April 12th 2024

Radiographic Progression Low for High-Risk Patients With axSpA on Both Secukinumab and an Adalimumab Biosimilar

Kimberly Rath, PharmD

Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.

Hand with psoriatic arthritis | Image credit: Iri-s - stock.adobe.com.jpg

April 4th 2024

Indirect Comparison Finds Bimekizumab More Effective Than Guselkumab in Psoriatic Arthritis

Laura Joszt, MA

Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.

Wooden blocks spelling biosimilar | Image credit: lexiconimages - stock.adobe.com

March 29th 2024

Data Support Safety, Efficacy of Biosimilar-to-Biosimilar Switching

Laura Joszt, MA

The majority of studies evaluating biosimilar-to-biosimilar switching were for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.

Man holding knee with knee pain | Image credit: wavebreak3 - stock.adobe.com

March 22nd 2024

Psychosocial Factors Increase Likelihood of Joint Pain in Psoriatic Arthritis

Laura Joszt, MA

A history of depression was the most predictive factor for developing persistent joint pain among patients with psoriatic arthritis.

Young black guy having heart attack, holding his chest - Prostock-studio - stock.adobe.com

March 19th 2024

Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study

Giuliana Grossi

Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.

Blood testing | Image credit: angellodeco - stock.adobe.com

March 15th 2024

Use of Recommended Tests Before Starting Immunomodulatory Agents for Chronic Inflammatory Skin Diseases Varies

A recent study found significant variation in the use of recommended laboratory tests ahead of immunomodulatory treatment in patients with chronic inflammatory skin diseases, with less than 60% of patients in the US receiving recommended pretreatment testing.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions